Detailed explanation of the most serious side effects of regorafenib (Belvango) and patient response measures

1. Overview of Regorafenib

Regorafenib (Regorafenib) is an oral multi-target tyrosine kinase inhibitor that mainly acts on angiogenesis, tumor microenvironment and multiple signaling pathways. Clinically, it is mainly used to treat patients with advanced colorectal cancer, gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma (HCC). By inhibiting angiogenesis and tumor growth-related signaling pathways, regorafenib can delay tumor progression and improve patients' progression-free survival (PFS). However, while the drug is effective, it may cause a variety of side effects, some of which are serious and require great concern.

2. Overview of the most serious side effects of regorafenib

Clinical research and practice show that the most serious side effects of regorafenib mainly include the following categories:

1.Hand-foot skin reaction (HFSR)

HFSR is the most common side effect of regorafenib and may seriously affect the quality of life, manifesting as erythema, pain, scaling, blisters and even ulcers on the palms and soles of the feet. Severe HFSR may affect walking, holding objects, or daily life, and requires timely intervention.

2.Hypertension

Regorafenib can cause a significant increase in blood pressure, and some patients may even develop hypertensive crisis. If not controlled in time, it may increase the risk of cardiovascular events, such as heart failure, myocardial infarction, or stroke.

3.Abnormal liver function

Drugs may cause ALT, AST and bilirubin to increase. In severe cases, acute liver injury may develop. Liver function abnormalities often appear early in treatment and require strict monitoring.

4.Bleeding and gastrointestinal complications

Regorafenib can increase the risk of bleeding, including nosebleeds, gum bleeding, or gastrointestinal bleeding. Some patients may develop severe diarrhea, gastrointestinal perforation or ulcers and require immediate medical attention.

5.Cardiovascular events

Although the incidence is low, regorafenib may cause serious cardiovascular adverse events such as heart failure, myocardial infarction, or prolongation of the QT interval, especially in patients with pre-existing heart disease. The risk is higher.

3. Detailed explanation of patient response measures

1.Management of hand-foot skin reaction (HFSR)

Mild to moderateHFSR: Use moisturizing cream, petroleum jelly or urea ointment to protect the skin and avoid friction or high temperature immersion; reduce prolonged standing or hand work.

SevereHFSR: It is necessary to temporarily stop the drug or reduce the dose of treatment. You can use local glucocorticoid-containing ointment and perform pain management under the guidance of a doctor.

2.Prevention and control of hypertension

Assess blood pressure and cardiovascular history before treatment, and self-measure blood pressure daily during treatment.

If blood pressure rises, promptly use antihypertensive drugs (such as ACEI, ARB or calcium antagonists) to control it, and adjust the dose of regorafenib under the guidance of a doctor.

In the event of hypertensive crisis, seek medical attention immediately and suspend medications.

3.Monitoring and treatment of abnormal liver function

Detect ALT, AST, bilirubin and ALP regularly before and during treatment.

Mild to moderate abnormalities can be observed or supplemented with hepatoprotective treatment. Severe increases or accompanied by jaundice require suspension or reduction of medication.

After liver function returns to normal, medication can be resumed under the guidance of a doctor.

4.Response to bleeding and gastrointestinal events

When symptoms of bleeding occur, seek medical attention immediately and perform laboratory and imaging tests if necessary.

Severe diarrhea or gastrointestinal perforation requires discontinuation of medication and hospitalization, and anti-infective or symptomatic treatment is also required.

Avoid concomitant use of anticoagulants or nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce the risk of bleeding.

5.Prevention and management of cardiovascular events

High-risk patients require cardiac evaluation, including electrocardiography and cardiac function testing, before treatment.

If chest pain, palpitations, or difficulty breathing occur during treatment, you should seek medical attention immediately and evaluate whether to suspend medication.

Patients with cardiovascular disease need to work with a cardiologist for drug management to ensure the safety of treatment.

4. Daily self-management suggestions for patients

1. Create a symptom record sheet

Patients should record daily weight, blood pressure, skin condition of hands and feet, frequency of diarrhea and other symptoms to facilitate doctors to evaluate side effects and adjust dosage.

2.Regular follow-up visits and laboratory monitoring

Doctors usually recommend rechecking blood routine, liver function and blood pressure every 2~4 weeks, and conducting imaging follow-up based on symptoms to detect side effects early.

3.Reasonable lifestyle

Avoiding high-salt and high-fat diets, exercising moderately, and maintaining a good routine can help control blood pressure and improve cardiovascular health, while reducing fatigue and edema caused by drugs.

4.Timely communication and medication compliance

If you encounter side effects or uncomfortable symptoms, you should inform the attending doctor in time to avoid stopping the medication or adjusting the dose on your own. Dosage adjustment or symptomatic treatment under the guidance of a doctor can ensure the efficacy and safety to the greatest extent.

Overall, regorafenib is effective, but the most serious side effects include hand-foot skin reaction, hypertension, abnormal liver function, bleeding, and cardiovascular events. Through standardized monitoring, early intervention and self-management, most side effects can be effectively controlled, thus ensuring safe medication use and optimal therapeutic effects for patients.

Reference link:https://www.drugs.com